Clinical trials: Healthy Volunteer, Type 2 Diabetes
Healthy, Type 2 Diabetes Mellitus (T2DM)
A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)
The main purposes of this study are to determine: The safety of tirzepatide and any side effects that might be associated with it. How much tirzepatide gets into the bloodstream and how long it takes the body to get rid of it.
- Trial name
- NCT02759107
- Testing
- Tirzepatide, Dulaglutide
- Where
- 2 sites in United States, Singapore
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability
The objective of the current study is to determine the relative bioavailability of a BI 10773 / metformin fixed dose combination tablet compared to single tablets of BI 10773 and metformin when administered together and to assess…
- Trial name
- NCT01211197
- Testing
- C: BI 10773 / metformin tablet, B: BI 10773 tablet and metformin tablet, A: BI 10773 / metformin tablet
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fed Conditions
The purpose of this clinical study is to evaluate the pharmacokinetics and safety between single oral administration of BR3006 and co-administration of BR3006A, BR3006B and BR3006C in healthy adult volunteers under fed conditions
- Trial name
- NCT06890299
- Testing
- BR3006, BR3006A, BR3006B
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Type 2 Diabetes Mellitus
Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered
To demonstrate bioequivalence of a 2.5 mg saxagliptin/850 mg metformin fixed dose combination (FDC) tablet relative to the 2.5 mg saxagliptin tablet and 850 mg metformin (Glucophage Marketed by Merck-Serono) tablet…
- Trial name
- NCT01068743
- Testing
- saxagliptin, metformin, saxagliptin + metformin (FDC tablet)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects
The purpose of this study is to determine the effects of LX4211 and metformin on each other when given at the same time as single doses to healthy human subjects.
- Trial name
- NCT01292993
- Testing
- 400 mg LX4211, 1000 mg metformin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Lexicon Pharmaceuticals
Healthy Subjects, Hyperlipidemias
Diurnal Triglyceridemia in Relation to Alcohol Intake
The purpose of this study is to determine the impact of alcohol consumption in diurnal triglyceridemia in a free living situation.
- Conditions
- Healthy Subjects, Hyperlipidemias, Type 2 Diabetes Mellitus, Cardiovascular Diseases
- Trial name
- NCT01786421
- Where
- 2 sites in Netherlands
- Volunteers
- 273 people, healthy volunteers welcome
- Sponsor
- Sint Franciscus Gasthuis
Type 2 Diabetes, Diabetes
The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers
This study, conducted at the Phoenix Indian Medical Center, Phoenix, Arizona, will determine whether reducing subclinical inflammation lessens insulin resistance in healthy, obese volunteers.
- Trial name
- NCT00339833
- Testing
- Salsalate
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.
A single blind, randomized, placebo-controlled, dose escalating study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic parameters of repeat doses of GSK2330672 in healthy volunteers, given alone and with…
- Trial name
- NCT01607385
- Testing
- GSK2330672, GSK1614235
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus (T2DM)
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM
To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-KHK and to evaluate the safety, tolerability, efficacy, PK and PD of multiple doses of KHK.
- Trial name
- NCT05761301
- Testing
- ALN-KHK
- Where
- 15 sites in United States, Canada
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Type 2 Diabetes Mellitus
Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects
The purpose of the study is to assess the effects of rifampin on the pharmacokinetics of dapagliflozin
- Trial name
- NCT01068756
- Testing
- Dapagliflozin, Rifampin
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Subjects, Obesity
Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
The phase 1 portion of the study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-6740 after single- and multiple-ascending doses in healthy subjects.
- Conditions
- Healthy Subjects, Obesity, Type 2 Diabetes
- Trial name
- NCT05822544
- Testing
- TLC-6740 Oral Solution, TLC-6740 Tablet, Drug Metabolizing Enzyme
- Where
- 4 sites in New Zealand
- Volunteers
- 564 people, healthy volunteers welcome
- Sponsor
- OrsoBio, Inc
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy Subjects
Primary Objective: To assess the relative bioavailability of sotagliflozin following single doses of 3 sotagliflozin prototype tablet formulations p1, p2 and p3 versus the reference tablet formulation in fasted conditions in…
- Trial name
- NCT03310944
- Testing
- sotagliflozin (SAR439954)
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Sanofi
Type II Diabetes Mellitus
Study to Evaluate the Safety and Pharmacokinetics of CKD-379
A study to compare the pharmacokinetics and safety between CKD-379 and D759, D745, D029, D150 combination
- Trial name
- NCT05952219
- Testing
- CKD-379, D759+D745+D029+D150
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes
Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393
Objective Evaluation of the pharmacokinetic properties and safety of CKD-393 0.25/50/750 mg oral administration in healthy adults under fed condition.
- Trial name
- NCT05113693
- Testing
- CKD-393, CKD-501, D759, H053
- Where
- South Korea
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus, Healthy Subjects
Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects
Primary Objective: To assess the absolute bioavailability of sotagliflozin via administration of an intravenous (IV) microdose of a 14C-sotagliflozin tracer on top of a single oral dose of unlabeled sotagliflozin without charcoal…
- Trial name
- NCT03802487
- Testing
- Sotagliflozin (SAR439954), 14C-microtracer, Charcoal
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study Of Three PF-05190457 Formulations In Healthy Volunteers
The purpose of the study is to evaluate the plasma drug concentrations of three formulations of PF-05190457 after administration of single doses to healthy volunteers.
- Trial name
- NCT01522807
- Testing
- PF-05190457
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes
Effect of a Simulated Flight in Patients With Type 2 Diabetes and Healthy Volunteers
Diabetes is an increasingly common condition which affects millions of people in the United Kingdom. Patients with type 2 diabetes are at increased risk to develop severe heart disease and vascular complications and these can…
- Trial name
- FlyBar (NCT04031417)
- Testing
- Hypoxia, Low Humidity
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Non-alcoholic Steatohepatitis, Type 2 Diabetes Mellitus (T2DM)
A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects
The Sponsor is developing the test medicine, cotadutide, for the potential treatment of non-alcoholic steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) with chronic kidney disease.
- Conditions
- Non-alcoholic Steatohepatitis, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease
- Trial name
- NCT05294458
- Testing
- cotadutide solution for injection
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers, Type 2 Diabetes
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets
In this study two different tablets for oral use of a known investigational medicinal product, called semaglutide, will be tested.
- Trial name
- NCT04109508
- Testing
- Oral semaglutide
- Where
- Germany
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
In this study, participants will receive semaglutide and NNC0480-0389 together at the same time. Semaglutide is a medicine that can already be prescribed, whereas NNC0480-0389 is a new potential medicine.
- Trial name
- NCT05046873
- Testing
- Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL, Semaglutide 1.34 mg/mL, NNC0480-0389 A 10 mg/mL
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S